Fornix and NbM as Targets of Stimulation In Alzheimer's Disease (FANTASIA)
A Randomized Controlled Study of 12 Months to Evaluate the Safety and Efficacy of Deep Brain Stimulation(DBS) to the Fornix & Meynert Nucleus(NbM) in Patients With Mild to Moderate Alzheimer's Disease(AD)
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Beijing, Cina, 100053
- Reclutamento
- Xuanwu Hospital, Capital Medical University.
-
Contatto:
- Peng-Hu Wei, M.D.
- Numero di telefono: +86-18601986863
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Subjects with informed consent;
- 45-75 years of age;
- At least 6 years of education;
- AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) guidelines (McKhann et al., 2011);
- Clinical Dementia Rating Scale (CDR): 1.0-2.0;
- Positive findings with amyloid PET imaging;
- Stable prescription of donepezil (5mg, qd) for at least 3 months, and without any intentions to modify the dosage during the observation period.
Exclusion Criteria:
- Fazekas scale>2;
- Neuropsychiatric inventory (NPI) total score ≥10, or any subdomain≥4；
- Modified Hachinski ischemic score>4；
- Young Mania Rating Scale>11(Young, Biggs, Ziegler, & Meyer, 1978);
- Any suicidal tendencies in recent 2 years;
- Cornell Scale for Depression and Dementia>10;
- Familial AD;
- Abnormal brain structural magnetic resonance imaging (MRI) scan, including hydrocephalus, stroke, structural lesions, etc. that would potentially confound the outcome;
- Surgical history of the central nervous system;
- Severe cardiovascular/pulmonary disorders.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: DBS of the fornix, power on
|
DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on . DBS system includes: Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead |
|
Sperimentale: DBS of the NbM, power on
|
DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on . DBS system includes: Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead |
|
Comparatore fittizio: DBS of the fornix, power off
|
DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation. DBS system includes: Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead |
|
Comparatore fittizio: DBS of the NbM, power off
|
DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation. DBS system includes: Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead |
|
Nessun intervento: Control group
The patients are going to prescribe stable dosage of donepezil during observation period without surgical interference.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cognitive outcome
Lasso di tempo: 12 months (from 1 month to 13 month after implantation)
|
Cognitive function measured by Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 13-items version). ADAS-cog 13 scale range: 0-80; (Higher value represents a worse outcome) |
12 months (from 1 month to 13 month after implantation)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Neuroplasticity outcome
Lasso di tempo: 12 months (from 1 month to 13 month after implantation)
|
Protection of hippocampal volume revealed by magnetic resonance imaging (MRI).
|
12 months (from 1 month to 13 month after implantation)
|
|
Neuroplasticity outcome
Lasso di tempo: 12 months (from 1 month to 13 month after implantation)
|
Improved cerebral metabolic level revealed by FDG positron emission tomography(PET) imaging.
|
12 months (from 1 month to 13 month after implantation)
|
|
Cognitive outcome
Lasso di tempo: 12 months (from 1 month to 13 month after implantation)
|
Improvement of cognitive function evaluated by Clinical Dementia Rating Scale sum of the boxes (CDR-SB). CDR-SB scale range: 0-18; ("0" represents normal cognition, the higher the score, the worse the cognitive function). |
12 months (from 1 month to 13 month after implantation)
|
|
Functional outcome
Lasso di tempo: 12 months (from 1 month to 13 month after implantation)
|
Improvement of life quality according to Activities of Daily Living (ADL) scale. ADL scale range: 20-80 ("20" represents normal life ability, the higher the score, the worse the life ability). |
12 months (from 1 month to 13 month after implantation)
|
|
Safety outcome
Lasso di tempo: 12 months (from 1 month to 13 month after implantation)
|
Device/therapy related side effects or complications such as mortality an morbidity.
|
12 months (from 1 month to 13 month after implantation)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- XuanwuH
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .